Dipexium Pharmaceuticals, Inc., a late stage pharmaceutical company, focuses on the development and commercialization of antibiotics in the United States. It develops Locilex (pexiganan cream 0.8%), a novel, broad spectrum, and topical antibiotic, which is in Phase 3 clinical trials for the treatment of mild infections of diabetic foot ulcers. The company was founded in 2010 and is based in New York, New York.
Reason for the huge drop: Dipexium Pharma (DPRX) Announces Locilex Phase 3s Missed Primary Endpoints Source: http://www.streetinsider.com/Corpor...ase+3s+Missed+Primary+Endpoints/12162153.html
Analyst Upgrade/Downgrade Update Brokerage firm: Feltl & Co. Change: Downgrade Previous Rating: Buy Current Rating: Hold Previous Price Target: N/A Current Price Target: N/A